NASH cirrhosis is the end stage of non-alcoholic steatohepatitis (NASH), where the scar tissue and regenerative nodules resulting from the inflammation and fibrosis of NASH has replaced healthy liver tissue, preventing the liver from functioning normally and potentially causing liver failure and death.
The NAVIGATE Study Phase 2b/3 clinical trial specifically targets NASH cirrhosis, seeking to prevent the development of varices and possibly other more serious complications of NASH cirrhosis.
Learn more about the NAVIGATE Study
NASH cirrhosis tends to worsen over time. Scar tissue and the formation of nodules progressively displace healthy liver tissue, ultimately causing liver failure.
NASH cirrhosis is fast becoming the leading cause of liver transplants in the U.S.
Varices are often the first sign that NASH cirrhosis has taken a turn for the worse.
The NAVIGATE Study seeks a way to prevent the development of esophageal varices, possibly preventing even more serious complications.
There is currently no cure for NASH cirrhosis apart from a liver transplantation. Current treatments are palliative and focus on keeping NASH cirrhosis from getting worse, through changes in lifestyle – weight loss, a healthy diet, and exercise – and avoiding things that stress the liver – alcohol, certain prescription medicines, and over-the-counter medicines.
The NAVIGATE Study may offer the first effective treatment for NASH cirrhosis.
There are a variety of information resources available to NASH cirrhosis patients and their families. These include:
Promotes education, advocacy, support services and research for the prevention, treatment and cure of liver disease.
Visit Site
Aims to improve the lives of individuals and families affected by liver disease.
Visit Site
Seeks to improve the diagnosis, treatment & support of Americans with fatty liver, NAFLD or NASH.
Visit Site
Established to increase public awareness of NAFLD and NASH through partnerships with other organizations with similar goals.
Visit Site
